WallStSmart

Canopy Growth Corp (CGC)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 974% more annual revenue ($3.15B vs $293.63M). UTHR leads profitability with a 41.6% profit margin vs -79.2%. UTHR earns a higher WallStSmart Score of 61/100 (C+).

CGC

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -12.96

UTHR

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CGC.

UTHRUndervalued (+0.8%)

Margin of Safety

+0.8%

Fair Value

$479.95

Current Price

$497.11

$17.16 discount

UndervaluedFair: $479.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

UTHR5 strengths · Avg: 9.4/10
Profit MarginProfitability
41.6%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
42.2%10/10

Strong operational efficiency at 42.2%

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 20 in profit

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$416.81M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-37.6%2/10

ROE of -37.6% — below average capital efficiency

Free Cash FlowQuality
$-25.75M2/10

Negative free cash flow — burning cash

UTHR2 concerns · Avg: 3.0/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

CGC profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.

CGC carries more volatility with a beta of 2.43 — expect wider price swings.

CGC is growing revenue faster at 12.5% — sustainability is the question.

UTHR generates stronger free cash flow (206M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (61/100 vs 36/100), backed by strong 41.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?